Bovie Medical Corp (BVX) 3.25 $BVX
4 Stocks Under $10 Making Big Moves Higher
at The Street - Tue Apr 21, 12:41PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
MELA: 1.52 (-0.14), ISR: 1.57 (+0.05), BVX: 3.25 (+0.40), AMDA: 0.29 (unch)
100 R&D Intensive Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjbtw4/randd_intensive) has announced the addition of the "R&D Intensive Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This newly launched report identifies 100 R&D Intensive medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Over the past few years the way the medical devices industry assesses innovation and new technology has changed. The old dynamic of the physician as judge of value has been replaced with the government, private insurers, and consumers increasingly determining what sells and at what price point. Consumers refuse to pay for incremental enhancements that add bells and whistles that do not improve health or reduce cost. The faster, better, smaller, cheaper innovations in medical devices are the devices that will maintain a sustainable advantage. Recently, global market has been taking the lead in developing lean, frugal, and reverse innovation. This type of innovation simplifies devices and processes, retaining essential functions, while applying new technologies that are more versatile, mobile, and adaptable to consumer's needs and are less expensive. The global companies in medical devices/technology industry are highly R&D intensive and technology based. Such companies, on an average, spend 12% of their revenues on R&D each year in order to develop, design, and commercialize innovative medical devices. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the R&D Intensive companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - R&D Intensive 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of R&D Intensive medical devices/technology/supplies companies with foreign companies - International presence of R&D Intensive medical devices/technology/supplies companies - Key R&D activities by R&D Intensive medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of R&D Intensive Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 R&D Intensive Medical Devices/Technology/Supplies Companies 3: Key News of R&D Intensive Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of R&D Intensive Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by R&D Intensive Medical Devices/Technology/Supplies Companies 6: International Presence of R&D Intensive Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of R&D Intensive Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3 D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/gj..._intensive
ATEC: 1.41 (+0.01), GBSNU: 15.40 (+1.15), MZOR: 13.10 (+0.34), FEIC: 74.80 (+0.88), ZLTQ: 33.42 (-0.59), IART: 59.75 (-0.26), BVX: 3.25 (+0.40)
Bovie Medical Corporation Announces Closing of Over-Allotment Option
Business Wire - Tue Mar 31, 10:34AM CDT
Bovie Medical Corporation ("Bovie" or the "Company"
(NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, announced today that it has closed the sale of an additional 418,749 shares of its common stock pursuant to the over-allotment option of the underwriter in connection with its recent public offering of common stock. After closing of the over-allotment, the total number of shares sold by Bovie in the offering is 5,218,749. The total net proceeds of the offering, after deducting underwriting discounts, commissions and estimated offering expenses, are approximately $11.6 million.
BVX: 3.25 (+0.40)
Genocea Bio and Bovie Med close equity offerings
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 10:15AM CDT
BVX: 3.25 (+0.40), GNCA: 12.48 (-0.23)
Bovie Medical Corporation Announces Closing of Public Offering of Common Stock
Business Wire - Tue Mar 17, 9:55AM CDT
Bovie Medical Corporation ("Bovie" or the "Company" (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, announced today that it has closed its previously-announced registered underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $2.50 per share. Bovie estimates net proceeds from the offering to be approximately $10.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. Bovie intends to use the proceeds from the offering for working capital and general corporate purposes.
BVX: 3.25 (+0.40)
Bovie Medical prices public offering at USD2.50 per share
M2 - Fri Mar 13, 6:13AM CDT
Medical devices company Bovie Medical (NYSE:BVX) said on Thursday that it has priced its public offering of 4,800,000 shares of its common stock.
BVX: 3.25 (+0.40)
Market Maker Surveillance Report. BVX, CMTL, CUR, PTX, ZAZA, PGEM, Losing Stocks With Lowest Price Friction For Thursday, March 12th 2015
M2 - Fri Mar 13, 4:17AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4980 companies with "abnormal" market making, 4213 companies with positive Friction Factors and 2020 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Thursday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Bovie Medical Corp (NYSE:BVX), Comtech Telecommunications Corp (NASDAQ:CMTL), Diagnocure Inc (NYSE:CUR), Pernix Therapeutics Holdings Inc (NASDAQ
TX), ZaZa Energy Corp (NASDAQ:ZAZA), (NYSE GEM). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CMTL: 30.97 (+0.12), PTX: 7.44 (-0.05), PGEM: 14.26 (+0.15), ZAZA: 1.44 (-0.02), BVX: 3.25 (+0.40), CUR: 1.96 (-0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 11:45AM CDT
BOX: 18.29 (+0.37), CMTL: 30.97 (+0.12), PTX: 7.44 (-0.05), PGEM: 14.26 (+0.15), AMRN: 2.34 (-0.05), AXN: 1.77 (+0.01), AAMC: 223.83 (-3.57), MEIL: 1.14 (-0.06), ECTE: 1.66 (+0.07), ACAD: 38.55 (-0.20), OME: 13.12 (+0.18), PQ: 2.54 (+0.02), BONT: 7.05 (-0.17), AVD: 10.97 (-0.51), BVX: 3.25 (+0.40), TISA: 3.39 (-0.01), SCLN: 8.99 (+0.04), ENRJ: 1.75 (+0.05), SPP: 2.14 (+0.07), CUR: 1.96 (-0.04)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 8:14AM CDT
GENE: 4.88 (-0.05), MHR: 2.34 (-0.07), ACAD: 38.55 (-0.20), SHAK: 62.00 (+2.00), BOX: 18.29 (+0.37), JASO: 10.36 (+0.36), CYBR: 65.53 (-0.84), AMRN: 2.34 (-0.05), INGN: 36.39 (-0.04), BVX: 3.25 (+0.40), LL: 33.86 (+0.50), LIVE: 3.19 (-0.07)
Bovie Med prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 6:41AM CDT
BVX: 3.25 (+0.40)
Bovie Medical Corporation Announces Pricing of Public Offering of Common Stock
Business Wire - Thu Mar 12, 6:00AM CDT
Bovie Medical Corporation ("Bovie" or the "Company" (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, today announced that it has priced an underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $2.50 per share. In addition, Bovie has granted the underwriter a 30-day option to purchase up to 720,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about March 17, 2015, subject to satisfaction of customary closing conditions.
BVX: 3.25 (+0.40)
Bovie Medical plans to issue common stock in public offering
M2 - Thu Mar 12, 5:56AM CDT
Medical device company Bovie Medical (NYSEMKT:BVX) said on Wednesday that it intends to launch its registered underwritten public offering of its common stock.
BVX: 3.25 (+0.40)
Bovie Med initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:43PM CDT
BVX: 3.25 (+0.40)
Bovie Medical Corporation Announces Proposed Public Offering of Common Stock
Business Wire - Wed Mar 11, 3:05PM CDT
Bovie Medical Corporation ("Bovie" or the "Company" (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, today announced a proposed registered underwritten public offering of its common stock, subject to market and other conditions. In addition, the Company intends to grant the underwriter an option to purchase additional shares equal to up to 15% of the aggregate number of shares to be sold in the offering.
BVX: 3.25 (+0.40)
Bovie Medical's (BVX) CEO, Robert Gershon on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 27, 12:05PM CST
BVX: 3.25 (+0.40)
Bovie Medical reports Q4 results
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 6:32AM CST
BVX: 3.25 (+0.40)
Bovie Medical Corporation Announces Fourth Quarter and Full Year 2014 Earnings Call
Business Wire - Mon Feb 09, 12:31PM CST
Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2014 on Friday February 27, 2015 before market open.
BVX: 3.25 (+0.40)
Bovie Medical Provides Update on Recent Developments for J-Plasma(R)
Business Wire - Mon Jan 12, 3:01PM CST
Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma(R), a patented new surgical product, today provided an update on recent developments for J-Plasma(R).
BVX: 3.25 (+0.40)
Bovie Medical Corporation Further Expands Its Direct Sales Force
Business Wire - Wed Dec 17, 7:30AM CST
Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma(R), a patented new surgical product, today announced that it has added two Senior Surgical Device Specialists to its direct sales force. They will be responsible for the J-Plasma(R) roll-out and growth in their assigned territories.
BVX: 3.25 (+0.40)
Bovie Medical Receives FDA 510(k) Approval for Bovie Ultimate(TM) Generator
Business Wire - Tue Dec 16, 8:31AM CST
Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma(R), a patented new surgical product, today announced that it has received FDA 510(k) approval for the Bovie Ultimate(TM) generator.
BVX: 3.25 (+0.40)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Tue Apr 21, 12:41PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
MELA: 1.52 (-0.14), ISR: 1.57 (+0.05), BVX: 3.25 (+0.40), AMDA: 0.29 (unch)
100 R&D Intensive Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjbtw4/randd_intensive) has announced the addition of the "R&D Intensive Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This newly launched report identifies 100 R&D Intensive medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Over the past few years the way the medical devices industry assesses innovation and new technology has changed. The old dynamic of the physician as judge of value has been replaced with the government, private insurers, and consumers increasingly determining what sells and at what price point. Consumers refuse to pay for incremental enhancements that add bells and whistles that do not improve health or reduce cost. The faster, better, smaller, cheaper innovations in medical devices are the devices that will maintain a sustainable advantage. Recently, global market has been taking the lead in developing lean, frugal, and reverse innovation. This type of innovation simplifies devices and processes, retaining essential functions, while applying new technologies that are more versatile, mobile, and adaptable to consumer's needs and are less expensive. The global companies in medical devices/technology industry are highly R&D intensive and technology based. Such companies, on an average, spend 12% of their revenues on R&D each year in order to develop, design, and commercialize innovative medical devices. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the R&D Intensive companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - R&D Intensive 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of R&D Intensive medical devices/technology/supplies companies with foreign companies - International presence of R&D Intensive medical devices/technology/supplies companies - Key R&D activities by R&D Intensive medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of R&D Intensive Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 R&D Intensive Medical Devices/Technology/Supplies Companies 3: Key News of R&D Intensive Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of R&D Intensive Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by R&D Intensive Medical Devices/Technology/Supplies Companies 6: International Presence of R&D Intensive Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of R&D Intensive Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3 D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/gj..._intensive
ATEC: 1.41 (+0.01), GBSNU: 15.40 (+1.15), MZOR: 13.10 (+0.34), FEIC: 74.80 (+0.88), ZLTQ: 33.42 (-0.59), IART: 59.75 (-0.26), BVX: 3.25 (+0.40)
Bovie Medical Corporation Announces Closing of Over-Allotment Option
Business Wire - Tue Mar 31, 10:34AM CDT
Bovie Medical Corporation ("Bovie" or the "Company"
(NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, announced today that it has closed the sale of an additional 418,749 shares of its common stock pursuant to the over-allotment option of the underwriter in connection with its recent public offering of common stock. After closing of the over-allotment, the total number of shares sold by Bovie in the offering is 5,218,749. The total net proceeds of the offering, after deducting underwriting discounts, commissions and estimated offering expenses, are approximately $11.6 million. BVX: 3.25 (+0.40)
Genocea Bio and Bovie Med close equity offerings
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 10:15AM CDT
BVX: 3.25 (+0.40), GNCA: 12.48 (-0.23)
Bovie Medical Corporation Announces Closing of Public Offering of Common Stock
Business Wire - Tue Mar 17, 9:55AM CDT
Bovie Medical Corporation ("Bovie" or the "Company"
(NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, announced today that it has closed its previously-announced registered underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $2.50 per share. Bovie estimates net proceeds from the offering to be approximately $10.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. Bovie intends to use the proceeds from the offering for working capital and general corporate purposes. BVX: 3.25 (+0.40)
Bovie Medical prices public offering at USD2.50 per share
M2 - Fri Mar 13, 6:13AM CDT
Medical devices company Bovie Medical (NYSE:BVX) said on Thursday that it has priced its public offering of 4,800,000 shares of its common stock.
BVX: 3.25 (+0.40)
Market Maker Surveillance Report. BVX, CMTL, CUR, PTX, ZAZA, PGEM, Losing Stocks With Lowest Price Friction For Thursday, March 12th 2015
M2 - Fri Mar 13, 4:17AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4980 companies with "abnormal" market making, 4213 companies with positive Friction Factors and 2020 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Thursday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Bovie Medical Corp (NYSE:BVX), Comtech Telecommunications Corp (NASDAQ:CMTL), Diagnocure Inc (NYSE:CUR), Pernix Therapeutics Holdings Inc (NASDAQ
TX), ZaZa Energy Corp (NASDAQ:ZAZA), (NYSE GEM). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . CMTL: 30.97 (+0.12), PTX: 7.44 (-0.05), PGEM: 14.26 (+0.15), ZAZA: 1.44 (-0.02), BVX: 3.25 (+0.40), CUR: 1.96 (-0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 11:45AM CDT
BOX: 18.29 (+0.37), CMTL: 30.97 (+0.12), PTX: 7.44 (-0.05), PGEM: 14.26 (+0.15), AMRN: 2.34 (-0.05), AXN: 1.77 (+0.01), AAMC: 223.83 (-3.57), MEIL: 1.14 (-0.06), ECTE: 1.66 (+0.07), ACAD: 38.55 (-0.20), OME: 13.12 (+0.18), PQ: 2.54 (+0.02), BONT: 7.05 (-0.17), AVD: 10.97 (-0.51), BVX: 3.25 (+0.40), TISA: 3.39 (-0.01), SCLN: 8.99 (+0.04), ENRJ: 1.75 (+0.05), SPP: 2.14 (+0.07), CUR: 1.96 (-0.04)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 8:14AM CDT
GENE: 4.88 (-0.05), MHR: 2.34 (-0.07), ACAD: 38.55 (-0.20), SHAK: 62.00 (+2.00), BOX: 18.29 (+0.37), JASO: 10.36 (+0.36), CYBR: 65.53 (-0.84), AMRN: 2.34 (-0.05), INGN: 36.39 (-0.04), BVX: 3.25 (+0.40), LL: 33.86 (+0.50), LIVE: 3.19 (-0.07)
Bovie Med prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 6:41AM CDT
BVX: 3.25 (+0.40)
Bovie Medical Corporation Announces Pricing of Public Offering of Common Stock
Business Wire - Thu Mar 12, 6:00AM CDT
Bovie Medical Corporation ("Bovie" or the "Company"
(NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, today announced that it has priced an underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $2.50 per share. In addition, Bovie has granted the underwriter a 30-day option to purchase up to 720,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about March 17, 2015, subject to satisfaction of customary closing conditions. BVX: 3.25 (+0.40)
Bovie Medical plans to issue common stock in public offering
M2 - Thu Mar 12, 5:56AM CDT
Medical device company Bovie Medical (NYSEMKT:BVX) said on Wednesday that it intends to launch its registered underwritten public offering of its common stock.
BVX: 3.25 (+0.40)
Bovie Med initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:43PM CDT
BVX: 3.25 (+0.40)
Bovie Medical Corporation Announces Proposed Public Offering of Common Stock
Business Wire - Wed Mar 11, 3:05PM CDT
Bovie Medical Corporation ("Bovie" or the "Company"
(NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, today announced a proposed registered underwritten public offering of its common stock, subject to market and other conditions. In addition, the Company intends to grant the underwriter an option to purchase additional shares equal to up to 15% of the aggregate number of shares to be sold in the offering. BVX: 3.25 (+0.40)
Bovie Medical's (BVX) CEO, Robert Gershon on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 27, 12:05PM CST
BVX: 3.25 (+0.40)
Bovie Medical reports Q4 results
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 6:32AM CST
BVX: 3.25 (+0.40)
Bovie Medical Corporation Announces Fourth Quarter and Full Year 2014 Earnings Call
Business Wire - Mon Feb 09, 12:31PM CST
Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2014 on Friday February 27, 2015 before market open.
BVX: 3.25 (+0.40)
Bovie Medical Provides Update on Recent Developments for J-Plasma(R)
Business Wire - Mon Jan 12, 3:01PM CST
Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma(R), a patented new surgical product, today provided an update on recent developments for J-Plasma(R).
BVX: 3.25 (+0.40)
Bovie Medical Corporation Further Expands Its Direct Sales Force
Business Wire - Wed Dec 17, 7:30AM CST
Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma(R), a patented new surgical product, today announced that it has added two Senior Surgical Device Specialists to its direct sales force. They will be responsible for the J-Plasma(R) roll-out and growth in their assigned territories.
BVX: 3.25 (+0.40)
Bovie Medical Receives FDA 510(k) Approval for Bovie Ultimate(TM) Generator
Business Wire - Tue Dec 16, 8:31AM CST
Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma(R), a patented new surgical product, today announced that it has received FDA 510(k) approval for the Bovie Ultimate(TM) generator.
BVX: 3.25 (+0.40)
